← Leaderboards
Melissa Jan Spencer
University Of California Los Angeles
$14,220,132
Attributed
$16,179,491
Total exposure
11
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.2M · FY2005–24$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$22,413,931 · 12
By mechanism
R01$12,755,467 · 4
P30$8,554,464 · 4
RC1$995,500 · 1
R03$76,500 · 1
R13$32,000 · 2
Top collaborators
- Jeffrey S Chamberlain5 shared
- M Carrie Miceli2 shared
- Stanley F. Nelson2 shared
Most similar at University Of California Los Angeles
Same institution · by research overlap
- James G Tidball$18,225,068
- M Carrie Miceli$7,403,834
- April D Pyle$6,193,530
- Julio L. Vergara$6,643,550
- Sotirios Tetradis$9,598,114
Others in their field
Top investigators on “Muscular Dystrophies”
- Jeffrey S Chamberlain · University Of Michigan At Ann Arbor$53,688,339
- Stephen J. Tapscott · Fred Hutchinson Cancer Center$24,320,230
- Elizabeth M McNally · University Of Chicago$24,290,327
- Eric P Hoffman · Reveragen Biopharma, Inc.$24,157,975
- Charles A Thornton · Virginia Commonwealth University$22,039,420
- Krista H Vandenborne · University Of Pennsylvania$21,082,899
Research focus
Muscular DystrophiesMusclePhenotypeMutationCalpainResearch PersonnelProteinsClinical TrialsMyopathyDesignPathway InteractionsLeadIn VivoCellsBaseGenesComplexBiochemicalDystrophinMouse ModelProgramsResourcesPeptide HydrolasesIn Vitro
Grant awards (60)
Optimizing and validation of gene therapy vectors to treat limb girdle muscular dystophy$481,106
R01 · FY2024 · NS · contact PI
Optimizing and validation of gene therapy vectors to treat limb girdle muscular dystophy$495,985
R01 · FY2023 · NS · contact PI
Optimizing and validation of gene therapy vectors to treat limb girdle muscular dystophy$496,020
R01 · FY2022 · NS · contact PI
Optimizing and validation of gene therapy vectors to treat limb girdle muscular dystophy$552,804
R01 · FY2021 · NS · contact PI
Optimizing and validation of gene therapy vectors to treat limb girdle muscular dystophy$565,469
R01 · FY2020 · NS · contact PI
FASEB SRC on Calpains in Health and Disease$23,000
R13 · FY2019 · NS · contact PI
UCLA Muscular Dystrophy Core Center$616,000
P30 · FY2018 · AR · contact PI
Administrative and Enrichment Core$315,700
P30 · FY2018 · AR · contact PI
Muscle Phenotyping and Imaging$107,800
P30 · FY2018 · AR · contact PI
UCLA Muscular Dystrophy Core Center$616,000
P30 · FY2017 · AR · contact PI
Muscle Phenotyping and Imaging$221,128
P30 · FY2017 · AR · contact PI
UCLA Muscular Dystrophy Core Center$616,000
P30 · FY2016 · AR · contact PI
Mechanisms Underlying Limb Girdle Muscular Dystrophy2A Due to Calpain 3 Mutations$497,095
R01 · FY2016 · AR · contact PI
Muscle Phenotyping and Imaging$221,128
P30 · FY2016 · AR · contact PI
UCLA Muscular Dystrophy Core Center$616,000
P30 · FY2015 · AR · contact PI
Mechanisms Underlying Limb Girdle Muscular Dystrophy2A Due to Calpain 3 Mutations$497,095
R01 · FY2015 · AR · contact PI
Muscle Phenotyping and Imaging$221,128
P30 · FY2015 · AR · contact PI
UCLA Muscular Dystrophy Core Center$616,000
P30 · FY2014 · AR · contact PI
Mechanisms Underlying Limb Girdle Muscular Dystrophy2A Due to Calpain 3 Mutations$487,153
R01 · FY2014 · AR · contact PI
Muscle Phenotyping and Imaging$221,128
P30 · FY2014 · AR · contact PI
UCLA Muscular Dystrophy Core Center$583,232
P30 · FY2013 · AR · contact PI
Mechanisms Underlying Limb Girdle Muscular Dystrophy2A Due to Calpain 3 Mutations$472,239
R01 · FY2013 · AR · contact PI
Muscle Phenotyping and Imaging Core$208,364
P30 · FY2013 · AR · contact PI
UCLA Muscular Dystrophy Core Center$613,927
P30 · FY2012 · AR · contact PI
Mechanisms Underlying Limb Girdle Muscular Dystrophy2A Due to Calpain 3 Mutations$497,095
R01 · FY2012 · AR · contact PI
Muscle Phenotyping and Imaging Core$231,162
P30 · FY2012 · AR · contact PI
UCLA Muscular Dystrophy Core Center$613,927
P30 · FY2011 · AR · contact PI
Pathogenic Mechanisms in Limb Girdle Muscular Dystrophies$355,344
R01 · FY2011 · AR · contact PI
Muscle Phenotyping and Imaging Core$231,162
P30 · FY2011 · AR · contact PI
UCLA Muscular Dystrophy Core Center$613,927
P30 · FY2010 · AR · contact PI
Identification of Enhancers of Therapeutic Exon Skipping for DMD$497,653
RC1 · FY2010 · AR
LGMD 2A Protein Calpain 3 and Its Binding to Titin$385,672
R01 · FY2010 · AR · contact PI
Pathogenic Mechanisms in Limb Girdle Muscular Dystrophies$362,993
R01 · FY2010 · AR · contact PI
Muscle Phenotyping and Imaging Core$155,989
P30 · FY2010 · AR · contact PI
UCLA Muscular Dystrophy Core Center$613,927
P30 · FY2009 · AR · contact PI
Identification of Enhancers of Therapeutic Exon Skipping for DMD$497,847
RC1 · FY2009 · AR
LGMD 2A Protein Calpain 3 and Its Binding to Titin$378,904
R01 · FY2009 · AR · contact PI
Pathogenic Mechanisms in Limb Girdle Muscular Dystrophies$360,083
R01 · FY2009 · AR · contact PI
Muscle Phenotyping and Imaging Core$185,335
P30 · FY2009 · AR · contact PI
UCLA Muscular Dystrophy Core Center$115,500
P30 · FY2009 · AR · contact PI
LGMD 2A Protein Calpain 3 and Its Binding to Titin$368,745
R01 · FY2008 · AR · contact PI
Pathogenic Mechanisms in Limb Girdle Muscular Dystrophies$353,696
R01 · FY2008 · AR · contact PI
LGMD 2A Protein Calpain 3 and Its Binding to Titin$366,399
R01 · FY2007 · AR · contact PI
Pathogenic Mechanisms in Limb Girdle Muscular Dystrophies$354,590
R01 · FY2007 · AR · contact PI
FASEB Summer Conference on: The Biology of Calpains in Health and Disease$9,000
R13 · FY2007 · AR · contact PI
LGMD 2A Protein Calpain 3 and Its Binding to Titin$367,661
R01 · FY2006 · AR · contact PI
THERAPEUTIC APPROACHES FOR MUSCULAR DYSTROPHY$348,594
R01 · FY2006 · AR · contact PI
LGMD 2A protein calpain 3 and its binding to titin$362,188
R01 · FY2005 · AR
THERAPEUTIC APPROACHES FOR MUSCULAR DYSTROPHY$356,983
R01 · FY2005 · AR
LGMD 2A protein calpain 3 and its binding to titin$362,188
R01 · FY2004 · AR
THERAPEUTIC APPROACHES FOR MUSCULAR DYSTROPHY$295,850
R01 · FY2004 · AR
THERAPEUTIC APPROACHES FOR MUSCULAR DYSTROPHY$50,615
R01 · FY2004 · AR
LGMD 2A protein calpain 3 and its binding to titin$362,188
R01 · FY2003 · AR
THERAPEUTIC APPROACHES FOR MUSCULAR DYSTROPHY$295,850
R01 · FY2003 · AR
LGMD 2A protein calpain 3 and its binding to titin$362,188
R01 · FY2002 · AR
THERAPEUTIC APPROACHES FOR MUSCULAR DYSTROPHY$296,011
R01 · FY2002 · AR
LGMD 2A protein calpain 3 and its binding to titin$353,123
R01 · FY2001 · AR
THERAPEUTIC APPROACHES FOR MUSCULAR DYSTROPHY$296,820
R01 · FY2001 · AR
THERAPEUTIC APPROACHES FOR MUSCULAR DYSTROPHY$316,721
R01 · FY2000 · AR
CALPAIN REGULATION OF MUSCLE NECROSIS AND REGENERATION$76,500
R03 · FY2000 · AR